Melanoma vaccine reduces the risk of cancer reoccuring or death by 49%

Embargoed until: Publicly released: 2024-06-03 22:00

Australia; International

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

An mRNA-based melanoma vaccine reduces the risk of cancer reoccurrence or death by 49% over 3 years,  according to a trial being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Australian of the Year, Prof Georgina Long is a primary investigator on the study. The vaccine, called mRNA-4157 (V940), has been developed by Moderna, and was given in combination with an immunotherapy drug called Keytruda. The results show that the 2.5-year recurrence-free survival rate for the vaccine in combination with Keytruda was 74.8%, compared to 55.6% for Kyetruda alone.